```
Under the Securities Exchange Act of 1934
(Amendment 1) (*)
(Name of Issuer)
                              Catalyst Biosciences, Inc.
(Title of Class of Securities) Common Stock
(CUSIP Number)
                              14888D208
(Date of Event Which Requires Filing of this Statement) April 13, 2017
(*) This amendment is a corrected copy of the original 13G filed on
April 13, 2017 in order to include Series A Convertible Preferred shares
and, exercisable warrants in the beneficial ownership calculation.
Check the appropriate box to designate the rule pursuant to which this
Schedule
is filed:
       ]Rule 13d-1(b)
X ]Rule 13d-1(c)
         ]Rule 13d-1(d)
     CUSIP No.
                              14888D208
         1. Names of Reporting Persons.
            Laurence W.Lytton
2. Check the Appropriate Box if a Member of a Group (See Instructions)
a).....a)
(b).....
     3.SEC Use Only
     4. Citizenship or Place of Organization
               USA
     5. Sole Voting Power
                              282,000 (1)
     6. Shared Voting Power
     7. Sole Dispositive Power 282,000 (1)
     8. Shared Dispositive Power
     9. Aggregate Amount Beneficially Owned by Each Reporting
     Person
                              282,000 (1)
      (1) includes 194,500 common shares, and 250 Series A Pfd Stock
      convertible into 50,000 common shares and warrants to purchase
      37,500 shares at an exercise price of $5.50 per share.
     10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     (See Instructions).....
     11. Percent of Class Represented by Amount in Row (9)
                              6.5% (2)
      (2) Based on 4,260,161 shares of common stock outstanding as of
      April 20, 2017, as reported in the Issuers Form 8-K filed with
      the SEC on April 24, 2017, plus the assumed conversion of reporting persons Series A Pfd Stock (50,000 shares if converted) and
```

warrants (37,500 shares if converted).

UNITED STATES

SCHEDULE 13G

Washington, D.C. 20549

SECURITIES AND EXCHANGE COMMISSION

12. Type of Reporting Person (See Instructions)

ΙN

Item 1.

(a) Name of Issuer Catalyst Biosciences, Inc.

(b)Address of Issuer's Principal Executive Offices

260 Littlefield Ave. South San Francisco, California

Item 2.

(a) Name of Person Filing Laurence W. Lytton

(b)Address of Principal Business Office or, if none, Residence

467 CPW N.Y., NY 10025

(c)Citizenship USA

(d)Title of Class of Securities Common

(e)CUSIP Number 14888D208

Item 3. not applicable

Item 4.Ownership.

(a) Amount beneficially owned: 282,000 (1).

(b)Percent of class: 6.5%

(c) Number of shares as to which the person has:

(i)Sole power to vote or to direct the vote 282,000 (1).

(ii)Shared power to vote or to direct the vote

(iii) Sole power to dispose or to direct the disposition of 282,000 (1).

(iv)Shared power to dispose or to direct the disposition of

Item 5.0wnership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ().

Item 6.0wnership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company $\left(\frac{1}{2} \right)$

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item 10.Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held

in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

rrect.	
5/1/17	
Date	
s/ Laurence W. Lytton	
Signature	
Laurence W. Lytton	
Name/Title	